Cell-Target-Specific Anti-Inflammatory Effect of Empagliflozin: In Vitro Evidence in Human Cardiomyocytes

Cell-Target-Specific Anti-Inflammatory Effect of Empagliflozin: In Vitro Evidence in Human Cardiomyocytes

The antidiabetic sodium–glucose cotransporter type 2 inhibitor (SGLT2i) empagliflozin efficiently reduces heart failure (HF) hospitalization and cardiovascular death in type 2 diabetes (T2D). Empagliflozin-cardioprotection likely includes anti-inflammatory effects, regardless glucose lowering, but t...

Full description

Bibliographic Details
Main Authors: Silvia Giannattasio, Anna Citarella, Sofia Trocchianesi, Tiziana Filardi, Susanna Morano, Andrea Lenzi, Elisabetta Ferretti, Clara Crescioli
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Molecular Biosciences
Subjects:
empagliflozin (EMPA)
SGLT2 inhibition
cardiomyocyte
cardioprotection
inflammation
CXCL10 (IP-10)
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2022.879522/full

Internet

https://www.frontiersin.org/articles/10.3389/fmolb.2022.879522/full

Similar Items